

Applicant: Jean-Claude Bystryn
U.S. Serial No.: 10/046,880
Filing Date: January 15, 2002
Page 2

1. (Currently Amended) A polyvalent vaccine ~~composition~~ useful for the treatment of human melanoma cancer, said vaccine ~~composition~~ comprising a physiologically acceptable diluent and a composition consisting essentially of multiple melanoma-associated cell surface antigens shed upon culturing multiple different human melanoma cell lines in serum-free medium for a period of time before said shed antigens are substantially degraded in said medium and wherein said shed antigens are partially separated from the bulk of cytoplasmic cellular components which are shed more slowly, said cell lines having been previously adapted to and maintained in a serum-free medium and are selected on the basis of shedding different molecular weight melanoma associated cell surface antigens during culturing in a serum-free medium.
2. (Currently Amended) A polyvalent vaccine ~~composition~~ useful for the treatment of human melanoma cancer, said vaccine comprising a ~~composition~~ physiologically acceptable diluent, an adjuvant, and a composition consisting essentially of multiple melanoma-associated cell surface antigens shed upon culturing human melanoma cell lines in serum-free medium for a period of time before said shed antigens are substantially degraded in said medium and wherein said shed antigens are partially separated from the bulk of cytoplasmic cellular components which are shed more slowly, said cell lines having been previously adapted to and maintained in a serum free medium and wherein the shed cell-surface antigens from multiple different cell lines are pooled.
3. (Cancelled)

Applicant: Jean-Claude Bystryn
U.S. Serial No.: 10/046,880
Filing Date: January 15, 2002
Page 3

4. (Currently Amended) A vaccine suitable for administration to a human for the treatment of human melanoma cancer, said vaccine comprising a physiologically acceptable diluent, an adjuvant, and an immunogenic composition of human melanoma associated cell surface antigens having been prepared by: (a) culturing in a serum free medium for a period of time before said cell surface antigens are substantially degraded in said medium and said shed antigens are partially separated from the bulk of cytoplasmic cellular components which are shed more slowly in a serum free medium, a pool of human melanoma cell lines wherein said cell lines are selected based on shedding different molecular weight cell surface melanoma associated antigens, said melanoma cells prior to culturing having been adapted to and maintained in a serum free culture medium; (b) subjecting the culture medium after culturing the melanoma cells therein to a particle separation operation for the removal of melanoma cells from said culture medium; (c) concentrating the resulting melanoma cell free culture medium which contains shed melanoma associated cell surface material therein, the material having been shed from the melanoma cell lines during culturing; and (d) recovering resulting shed melanoma cell antigen material and utilizing the recovered shed antigen material in the preparation of the vaccine comprising said melanoma associated cell surface antigens.

5. (Cancelled)

6. (Cancelled)

Applicant: Jean-Claude Bystryn
U.S. Serial No.: 10/046,880
Filing Date: January 15, 2002
Page 4

7. (Cancelled)
8. (Cancelled)
9. (Cancelled)